Treating difficult anal fistulas with risankizumab
Treatments studied
Part of Digestive system clinical trials.
This trial tests a drug called risankizumab (Skyrizi) for people whose Crohn's disease has led to anal fistulas that haven't improved with other treatments. The goal is to see if risankizumab can help these fistulas heal and stop draining.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 15 years old or older.
- You have a perianal fistula (a tunnel near the anus) confirmed by an MRI scan and it has been draining for at least 2 weeks.
- You have at least 1 and up to 2 internal openings and up to 3 external openings from the fistula.
- You have not responded well to or could not tolerate at least one of these treatments: antibiotics, immunomodulators, or advanced therapies like infliximab or adalimumab.
- You cannot have an ostomy (colostomy or ileostomy) or have had certain types of fistulas or strictures.
- You are not taking systemic steroids or have active infections or other serious medical conditions.
- You agree to have any seton (a temporary drainage thread) removed by week 20 of treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing whether a drug called mirikizumab, given alongside surgery to repair anal fistulas, can help heal them better in people with Crohn's disease. It aims to provide a new treatment option that may improve healing and quality of life.
This trial tests whether risankizumab can help people with a type of Crohn's disease where the intestine becomes narrowed (fibrostenotic) and causes symptoms like cramping or vomiting. The goal is to see if the drug can reduce inflammation and improve these blockages.
This study looks at how well ustekinumab works on its own for people with perianal fistulizing Crohn's disease, a type of Crohn's that causes painful tunnels near the anus. If you are already taking ustekinumab without other Crohn's medicines, this trial may help show if it can improve your fistulas.
This study follows children with Crohn's disease who have already started taking risankizumab. It aims to see how well the treatment works in real-world use.
This trial compares two drugs, guselkumab and risankizumab, to see which works better for people with moderate-to-severe Crohn's disease. Both are given as injections and aim to reduce inflammation in the gut.
This study tests whether adjusting the dose of infliximab (a biologic medicine given by IV) based on drug levels in your blood works better for treating draining fistulas caused by Crohn's disease. It is for people who have not tried other biologics and whose fistulas have not healed with usual treatments.
Hear when a new Perianal Fistula trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.